2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2734

Validation and Comparison Study of Immunoassays for the Measurement of Golimumab and Antibodies to Golimumab in Rheumatic Patients
Abstract Number: 2735

Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?
Abstract Number: 2736

Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis
Abstract Number: 2737

Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program
Abstract Number: 2738

A Comparison of EQ5D Index from the UK, US, and Japan Preference Weights Model, and Mapping Algorithm from Clinical Outcomes in Patients with Rheumatoid Arthritis: Results from Golimumab Intravenous Study
Abstract Number: 2739

Survival of Etanercept (ETN) Responders after Methotrexate (MTX) Failure When ETN Is Initiated As Mono or Combination Therapy or after MTX Withdrawal from ETN/MTX Combination in Long Standing Rheumatoid Arthritis (RA). a Single Center Retrospective Study
Abstract Number: 2740

ACPA Positivity in the Elderly and Concomitant MTX Use in Younger May be Useful Predictive Factors for Superior Clinical Efficacy with Abatacept in Japanese Biological-Naïve RA Patients
Abstract Number: 2741

An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Abstract Number: 2742

Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis
Abstract Number: 2743

Treatment Target Status at 6 Months and Long-Term Outcomes at 5 Years: Analysis of Methotrexate-Naïve Patients with Rheumatoid Arthritis
Abstract Number: 2744

What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry
Abstract Number: 2745

Real World Evaluation of Patients with Rheumatoid Arthritis Initiating Tofacitinib Vs. Adalimumab and Etanercept
Abstract Number: 2746

Comparison Study of Tests Available to Monitor Tocilizumab Therapy in Rheumatic Patients
Abstract Number: 2747

Study Completion and Etanercept Retention in Patients with Rheumatoid Arthritis Treated with Etanercept Monotherapy Versus Etanercept and Methotrexate Combination Therapy
Abstract Number: 2748

Evaluation of Patient-Reported Outcomes By Baseline Disease Duration: 6-Month Data from Two Clinical Trials of Patients with Early Rheumatoid Arthritis Treated with Abatacept

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].